MedTrace Logo

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

NCT04667910 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-27

No results posted yet for this study

Summary

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to CRVO

Conditions

  • Central Retinal Vein Occlusion

Interventions

DRUG

601 1.25mg

Solution for injection (intravitreal use)

DRUG

Ranibizuman 0.5 mg

Solution for injection (intravitreal use)

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiao rong Li, MD · TianJing Medical University Eye Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-27
Primary Completion
2022-11-16
Completion
2022-11-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04667910 on ClinicalTrials.gov